Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect
To the Editor:
Recurrent severe asthma exacerbations are associated with decreased lung growth or accelerated loss of lung function and add substantially to both the cost and morbidity associated with asthma. Risk factors for acute exacerbations include previous acute exacerbation, young age, poorly controlled asthma, and, in particular, viral respiratory tract infections. Exacerbations in school-aged children have been associated with sensitization to aeroallergens, particularly severe exacerbations requiring hospitalization, in which up to 90% of the affected group is atopic and has a viral infection. 1 This apparent comorbidity is the subject of ongoing controversy, but recent studies have provided a plausible and testable hypothesis that might explain how atopy contributes to the exacerbation process. 1 Notably, cross-linking of highaffinity IgE receptors (FcεRI) on plasmacytoid dendritic cells 2 and myeloid dendritic cells 3 of atopic subjects at airway mucosal infection sites, leading to attenuation of type 1 interferon production and enhancement of proinflammatory T H 2 cytokine production, respectively, markedly amplifies local inflammation. [1] [2] [3] This amplification process is IgE dependent, and hence blocking of available IgE during winter periods, which are at high risk for viral infection, might protect against these events.
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Several recent studies support this general concept. First, the addition of omalizumab, a humanized IgG 1 anti-IgE mAb, to regular inhaled steroids given to children with inadequately controlled atopic asthma reduced their exacerbations by 43% compared with placebo. 4 Second, in the Inner-City Asthma Study the addition of omalizumab to guidelines-based therapy reduced the number of days with asthma symptoms and reduced the proportion of study participants having 1 or more exacerbations from 48.8% to 30.3% across the 1-year treatment period. The strongest effect was on exacerbations occurring during the fall virus season. 5 Third, short-term preseasonal treatment with omalizumab blunted the ensuing fall asthma ''epidemic'' in atopic schoolchildren. 6 An important question arising from these observations is whether reducing virus-associated exacerbations in a single season is a sufficient ''circuit breaker'' to decelerate progression of asthma toward chronicity. To test this, we conducted a doubleblind, randomized, controlled 2-year pilot study of 27 children (58 screened; age, 6-15 years [mean, 11.45 6 2.99 years]; 14 male subjects) with a history of a severe asthma exacerbation in the previous winter (clinical trial registration ACTRN 12611001106921). Details of the study protocol and methods are shown in the Methods section in this article's Online Repository at www.jacionline.org. All children were sensitized to aeroallergens and had asthma for a mean of 7.7 years (SD, 4.5 years). Demographic and clinical characteristics are shown in Table I , with no important differences between groups. Children received omalizumab (n 5 14) or placebo (n 5 13) injections every 2 (n 5 15) to 4 (n 5 12) weeks based on their baseline total IgE level, per the manufacturer's recommendations (see Table E1 in this article's Online Repository at www.jacionline.org), for 5 months to 7 Children were assessed at the time of each injection at the end of the treatment period and then followed without treatment through the following year (follow-up period). The study schedule and procedures are shown in the Methods section in this article's Online Repository (also see Table E2 in this article's Online Repository at www.jacionline. org). Primary comparisons between groups were made by using negative binomial regression.
Twenty-five children completed the treatment, and 22 completed the follow-up. Despite the small number, significantly fewer severe asthma exacerbations were seen in children treated with omalizumab (n 5 1) than placebo (n 5 6), with an incident rate in the placebo group 10.8 times greater than that in the omalizumab group (P 5 .024). The time to first severe exacerbation was longer in those receiving omalizumab (mean, 240.5 days [SD, 87.9 days] vs 107.0 days [SD, 115.9 days]; P 5 .08; Fig 1) . There were no differences in the number of moderate exacerbations (incident rate, 1.24; P 5.58), time to first moderate exacerbation (177.3 days [140.6 days] vs 87.3 days [89.6 days], P 5 .91), or rate of lower respiratory tract illnesses (incident rate, 1.52; P 5 .11) between the study groups. The reduction in severe exacerbations was not seen during the follow-up period (incident rate, 0.45; P 5 .45). No statistically significant or clinically important changes were seen in lung function. We attempted to perform methacholine challenges at baseline, after treatment, and after follow-up, but many of the children were not able to perform the test because of low baseline lung function. In those able to participate (n 5 15), there were no differences in PD 20 values between the groups at any time point or any trend for reduction in methacholine responsiveness in either group.
The small numbers of children in this study means that our results must be treated with caution because our prestudy sample size calculations suggested that we needed 42 subjects per group to have 80% power to detect a 50% reduction in severe exacerbations with omalizumab. In addition, members of the placebo group were taking higher doses of inhaled corticosteroids, raising the possibility of less-well controlled asthma. However, they had a similar number of severe exacerbations in the previous 12 months (Table I) . Nevertheless, taken in conjunction with similar recent findings on omalizumabmediated blunting of the ''fall'' epidemics in susceptible children, 6 they do support the general concept of targeted disruption of atopy-associated pathways during periods of high risk as an asthma treatment strategy. Our findings of a lack of carryover of the protective effect of omalizumab treatment in a single virus season into the subsequent year leaves open the question of whether omalizumab can halt disease progression. This important question needs to be addressed in subsequent prospective studies. Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone
To the Editor: Dysregulated type 2 inflammation is associated with a number of allergic and atopic diseases, such as asthma, allergic rhinitis, and atopic dermatitis. The interplay between innate and adaptive immune pathways manifests in uncontrolled inflammation and ultimately tissue damage. Emerging data reveal the significance of type 2 cytokines, IgE, and eosinophils to the pathophysiology of these diseases. This is most appreciated in asthma, where numerous trials have demonstrated the clinical benefit of blocking type 2 cytokines, particularly in patients displaying elevated expression of pathway-specific type 2 biomarkers such as blood eosinophils.
1 Two components of type 2 immunity implicated in asthma pathogenesis are the cytokines IL-13 and IL-33, with cellular and genetic data supporting a role for IL-33 in regulating IL-13 expression. 2 It is appreciated that loss of either the IL-33 pathway or the IL-13 pathway attenuates type 2 inflammatory responses, revealing the nonredundant roles for these individual cytokines in vivo. However, whether the absence of the IL-33 signal impacts type 2 immunity solely due to a reduction in IL-13 or due to inhibition of additional inflammatory pathways remains unclear.
To address this hypothesis, we evaluated their individual versus combined contribution to type 2 immunity in vivo using 2 distinct models of pulmonary inflammation. Given the clinical relevance of eosinophils to asthma pathogenesis, we focused on examining how these pathways impact this cell type during inflammation. 1 Infection of rodents with the nematode Nippostrongylus brasiliensis causes an acute type 2 inflammatory response in the lung and intestine, characterized by eosinophil mobilization into the tissues and type 2 cytokine production (IL-4, IL-5, IL-13). 3 Because we were interested in evaluating these pathways in the context of their relevance to human asthma, we focused on examining the airway inflammation that is associated with this model. Wild-type (Il1rl1 ) were infected with N Brasiliensis larvae in the presence of control or IL-13-blocking antibodies (Fig 1, A) . This allowed us to assess the individual and combined contributions of IL-33 and IL-13 to the antihelminthic response. Consistent with previous reports, N Brasiliensis infection caused robust eosinophilic inflammation in both the bronchoalveolar lavage fluid and lung tissue of Il1rl1 1/1 mice, which was significantly diminished in Il1rl1 2/2 mice (Fig 1, B and C) . 4 Likewise, treatment of Il1rl1 1/1 mice with a neutralizing antibody to IL-13 resulted in a marked reduction in bronchoalveolar lavage fluid and tissue eosinophils. Remarkably, the combined loss of both the IL-33 and IL-13 signals led to an even greater inhibition of eosinophil mobilization into the lung, with levels comparable to those in the naive controls. Although eosinophilia showed greater reduction with coblockade, other features of airway inflammation were more sensitive to the absence of one pathway over another. Although the induction of the innate type 2 lymphocyte population, considered a dominant source of type 2 cytokines in this model, was diminished in the Il1rl1 2/2 mice, this cell type was unperturbed by loss of IL-13 activity (Fig 1, D) . 4 In accord with the reduction in innate type 2 lymphocyte cells, expression of IL-5 and IL-13 was attenuated in the Il1rl1 2/2 mice (Fig 1,  E; see Fig E1 in this article's Online Repository at www. jacionline.org). However, induction of the pathogenic mucin Muc5ac and mucus-driven goblet cell hyperplasia were dependent on IL-13 (see Fig E2 in this article's Online Repository at www.jacionline.org).
The question of redundancy between the IL-33 and IL-13 pathways during chronic antigen-stimulated pulmonary allergic inflammation was addressed using the 2,4,6-trinitrophenyl ovalbumin (TNP-OVA) sensitization/challenge model. This model is characterized by eosinophil mobilization into the airways stemming from an adaptive immune response to antigen.
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Il1rl1
1/1 and Il1rl1 2/2 mice were sensitized with TNP-OVA/ alum and challenged with TNP-OVA. Again, to address the combined effects of IL-33 and IL-13, mice were treated with control or anti-IL-13-blocking antibodies (Fig 2, A) . Consistent with published literature, eosinophilic inflammation induced by TNP-OVA sensitization/challenge is distinctly reduced in the absence of either the IL-33 pathway or the IL-13 pathway (Fig 2, B and C) . 5, 6 Similar to what we observed in the N Brasiliensis infection study, the combined blockade of both IL-33 and IL-13 signaling decreased eosinophil influx to the lung to levels seen in naive mice. Analysis of T-cell recall responses to TNP-OVA antigen also demonstrated that the absence of both pathways had a greater effect on IL-13 and IL-5 production over inhibition of each cytokine alone (Fig 2, D) . Again, we observed mucus-mediated pathologies to be promoted by IL-13. Methacholine-induced airway hyperreactivity, driven by Mucin 5AC production, was completely blocked by anti2IL-13 (see Fig E3 in this article' s Online Repository at www.jacionline.org). 7 The beneficial effect of coblockade on eosinophil mobilization was remarkable because of the clinical significance of this cell type. To elucidate possible mechanisms, we focused on IL-5, an
METHODS Study
This study was a phase 3, multicenter, double-blind, randomized, placebocontrolled study testing the efficacy of winter-only treatment with omalizumab for the reduction of asthma exacerbations in children aged 6 to 15 years. Clinical sites included the Royal Children's Hospital, Brisbane, Australia (site investigator: Professor Peter Sly); Royal Children's Hospital, Melbourne, Australia (site investigator: Professor Mimi Tang); and Princess Margaret Hospital, Perth, Australia (site investigator: Professor Peter LeSouef). The study population included children aged 6 to 15 years with asthma who were prone to acute exacerbations. Ninety-six children will be randomized. Randomization occurred in blocks stratified by study site based on predetermined block sizes.
Inclusion criteria
Participants who met all of the following criteria were eligible for enrollment:
1. children of either sex, aged 6 to 15 years, with current asthma; 2. admission to a hospital emergency department in the previous winter season for acute asthma exacerbation, as defined by the ATS/ERS statement on asthma control and exacerbations; 3. positive skin prick test responses to aeroallergens; 4. atopic family history; and 5. written informed consent form signed and dated by parent/legal guardian according to local regulations.
Exclusion criteria
Participants who met any of the following criteria were not eligible for enrollment:
1. hypersensitivity to omalizumab; 2. treatment with omalizumab within 30 days before screening; 3. use of prolonged high-dose oral steroids; 4. participation in another randomized controlled trial within the 3 months preceding inclusion in the study; and 5. a significant medical disease or condition other than asthma likely to interfere with the child's ability to complete the entire protocol.
Study design
The study was conducted as a multicenter, double-blind, randomized, placebo-controlled study testing the efficacy of omalizumab treatment during winter for the reduction of asthma exacerbations in children with exacerbation-prone asthma. Children identified from emergency department records as having an acute asthma exacerbation during the previous winter viral season and found eligible in the screening visit were randomized into 2 groups. The active group received omalizumab every 2 or 4 weeks for 5 months timed to cover the winter viral season (April/May to September/ October). The control group received identical placebo. Omalizumab was administered by means of subcutaneous injection every 2 or 4 weeks based on the baseline serum total IgE level (in international units per milliliter) measured before the start of treatment and body weight (in kilograms). The dosing regimen is shown in Table E1 .
E1 All children also received standard asthma therapy, as prescribed by their treating pediatrician.
Primary efficacy end point
The primary efficacy end point was the proportion of children with acute asthma exacerbations, as defined by the ATS/ERS statement on asthma control and exacerbations, E2 during the treatment period (ie, from visit 1 [first dosing] to visit 6 [1 month after the last dose]). Severe and moderate exacerbations were treated separately. 
Secondary efficacy end points
Data Safety Monitoring Board
Safety data were presented by group in a blinded fashion to the Data Safety Monitoring Board (DSMB) at scheduled DSMB meetings during the trial. The DSMB had the authority to request unblinded data, if necessary. The DSMB had the authority to recommend that enrollment or study treatment be discontinued for the safety of participants. Although the DSMB was to examine all safety data, they were requested to pay particular attention to the number of episodes of anaphylaxis.
Study procedures
Procedures conducted as a part of the participant's routine clinical management and obtained before informed consent were allowed to be used for screening purposes or assessment of eligibility criteria. However, the procedure must have met the protocol-defined criteria and have been performed within the timelines permitted by the protocol.
Informed consent
A signed written informed consent form was obtained from the participant's parent/legal guardian before any study-specific assessments or procedures.
Asthma control
The Childhood Asthma Control Test for children 11 years and younger and the Asthma Control Test for children 12 years and older were performed at visits 0, 6, and 18 to document asthma control.
Analysis sample
The following groups of participants will define samples for end point analysis:
d Intention-to-treat sample: All participants who are randomized and have evaluable data for the end point under investigation. Participants will be analyzed in the group to which they were randomized, regardless of compliance with their allocated treatment. The number of participants who have evaluable data might differ for each end point being investigated. d Safety sample: All participants who take at least 1 dose of the investigational product.
Statistical analysis
The primary data on asthma exacerbations and lower respiratory tract infections were not normally distributed and did not fit with a Poisson distribution. Because the dates were overdispersed (ie, the variance was greater than the mean), negative binomial regression was used for these primary analyses. Kaplan-Meier survival analyses were used to examine the time to first exacerbation, with the log-rank test used to test the difference in survival between treatment groups. Group differences in demographic data were tested by using the Wilcoxon rank sum test for continuous variables and the x 2 test for categorical variables.
Schedule of study assessments and procedures
A schedule of study visits, procedures, and assessments is shown in Table E2 . 
RESULTS
Asthma Control Test scores
